Correlation Between Refractory Laryngopharyngeal Reflux Disease and Symptoms of Anxiety and Depression
Fengling Huang,Qiu Liao,Xingkun Gan,Wensheng Wen
DOI: https://doi.org/10.2147/NDT.S349933
IF: 2.989
2022-04-26
Neuropsychiatric Disease and Treatment
Abstract:Fengling Huang, Qiu Liao, Xingkun Gan, Wensheng Wen Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530000, People's Republic of China Correspondence: Wensheng Wen, Department of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Guangxi Medical University, Shuangyong Road, No. 6, Nanning, Guangxi, 530000, People's Republic of China, Tel +86 0771-53556511, Email Background and Study Aims: The occurrence, development, and prognosis of refractory laryngopharyngeal reflux disease (LPRD) may be related to anxiety and depression. Our study aims to investigate anxiety and depressive symptoms in LPRD and clarify the correlations among them. Patients and Methods: Twenty-eight patients were diagnosed with LPRD and subsequently referred to the Department of Mental Health for treatment. The patients were divided into the Self-rating Anxiety Scale (SAS)/Self-rating Depression Scale (SDS) positive group (+) and the SAS/SDS negative group (−). All patients were treated (oral administration) with a standard dose of proton pump inhibitor (PPI, omeprazole 20 mg bid) plus one tablet of Deanxit (flupentixol-melitracen) after breakfast. Treatment efficacy was evaluated after one month of drug treatment. The therapeutic effect of PPI treatment alone was compared with that treated with PPI + Deanxit. Results: Among 28 patients with refractory LPRD, the main reflux symptoms and signs were specific. There were differences in gender distribution and age distribution among the 28 patients with refractory LPRD, and there were 17 patients (60.7%) in the SAS/SDS (+) group and 11 patients in the SAS/SDS (−) group (39.3%). Regarding efficacy evaluation after one month of PPI + Deanxit treatment, the differences in indices before and after treatment were statistically significant (all p < 0.05). Conclusion: Anxiety and depressive symptoms influence the occurrence, development, and treatment efficacy of refractory LPRD. Attention to and targeted treatment of anxiety and depressive symptoms can help improve the treatment outcomes of patients with refractory LPRD. Keywords: refractory, laryngopharyngeal reflux, anxiety, depression Laryngopharyngeal reflux (LPR) refers to the phenomenon of stomach contents flowing back to areas above the upper esophageal sphincter (including the nasal cavity, mouth, pharynx, larynx, trachea, and lungs). 1 Laryngopharyngeal reflux disease (LPRD) is a common diagnosis in outpatient otolaryngology clinics, and its incidence increases year by year. Domestic and foreign attention to and research on LPRD is also increasing. 2 However, the pathogenesis of LPRD remains unclear, as it is a disease with multiple etiological factors. 3 Development throughout the modern era has also promoted a fast-paced lifestyle. People face more challenges and pressure and have gradually recognized the physiological-psychological-social disease mode in the understanding of diseases. When LPRD cannot be controlled for a long period, namely, when symptoms do not exhibit obvious remission after proton pump inhibitor (PPI) treatment for 2 months or longer, psychological disorders are common sequelae. Generally, anxiety and depressive symptoms are frequent. In addition, patients with LPRD are likely to present chest distress, dizziness, and other physical-discomfort symptoms without organic pathological changes on cardiovascular and cerebrovascular examinations. Therefore, this study aims to investigate the relationship between refractory LPRD, anxiety and depressive symptoms, and autonomic nerve dysfunction. Twenty-eight patients diagnosed with suspected LPRD at the Department of Otolaryngology at our hospital via the reflux symptom index (RSI), and a reflux symptom rating scale (reflux finding score, RFS) from March 2009 to September 2019 were randomly selected. The inclusion criteria were as follows: between 20 and 65 years of age, either gender, education level of elementary school and above, and able to complete forms to provide relevant information. Through an examination by the same senior chief physician of our department, patients were diagnosed with LPRD when they presented typical manifestations of pharyngeal foreign body sensation, persistent clearing of the throat combined with clinical manifestations and RSI scores and/or reflux symptom rating scale scores (RFS) indicative of LPRD. Furthermore, after treatment with a PPI (omeprazole 20 mg bid), as prescribed by doctors in our hospital or other hospitals, for at least two months, the patients felt no significant symptom relief. The exclusion criteria were as follows: recent occurrence of a neck mass or malignant tumor of the throat revealed by electron -Abstract Truncated-
psychiatry,clinical neurology